Status:
UNKNOWN
Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Pregnancy Early
Miscarriage
Eligibility:
FEMALE
18-45 years
Phase:
PHASE4
Brief Summary
Gonadotropin Releasing Hormone agonist (GnRHa) triggering is used as an alternative to human chorionic gonadotropin (hCG) in GnRH antagonist protocol to eliminate the risk of ovarian hyperstimulation ...
Detailed Description
The administration of human chorionic gonadotropin (hCG) for final oocyte maturation is an accepted practice in in vitro fertilization (IVF) treatments. However, in high-responder patients, it increas...
Eligibility Criteria
Inclusion
- High responder patients, defined as either reaching a serum estradiol levels of ≥ 3500 pg/ml on the day of trigger or having ≥ 15 oocytes retrieved.
- Increased risk for OHSS (PCOS, previous history of OHSS, high antral follicle count (AFC) etc.).
Exclusion
- Repeated implantation failure (3 or more previous failed embryo transfer cycles while transferring good quality embryos).
- Oocyte donation, fertility preservation or Freeze all (freezing all the embryos) cycles.
- Moderate to severe endometriosis
- An evidence of hydrosalpinx
Key Trial Info
Start Date :
December 29 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04797338
Start Date
December 29 2017
End Date
September 30 2021
Last Update
April 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shamir Medical center
Be’er Ya‘aqov, Israel